CO2022014490A2 - Compuestos inhibidores de phd, composiciones y uso - Google Patents

Compuestos inhibidores de phd, composiciones y uso

Info

Publication number
CO2022014490A2
CO2022014490A2 CONC2022/0014490A CO2022014490A CO2022014490A2 CO 2022014490 A2 CO2022014490 A2 CO 2022014490A2 CO 2022014490 A CO2022014490 A CO 2022014490A CO 2022014490 A2 CO2022014490 A2 CO 2022014490A2
Authority
CO
Colombia
Prior art keywords
disease
pulmonary
acute
heart disease
compositions
Prior art date
Application number
CONC2022/0014490A
Other languages
English (en)
Spanish (es)
Inventor
Paul E Fleming
Thomas P Blaisdell
Senkara Rao Allu
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of CO2022014490A2 publication Critical patent/CO2022014490A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2022/0014490A 2020-03-20 2022-10-12 Compuestos inhibidores de phd, composiciones y uso CO2022014490A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062992585P 2020-03-20 2020-03-20
PCT/US2021/023219 WO2021188936A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and use

Publications (1)

Publication Number Publication Date
CO2022014490A2 true CO2022014490A2 (es) 2022-10-21

Family

ID=75639962

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014490A CO2022014490A2 (es) 2020-03-20 2022-10-12 Compuestos inhibidores de phd, composiciones y uso

Country Status (13)

Country Link
US (1) US20230227426A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121425A1 (cg-RX-API-DMAC10.html)
JP (2) JP7768890B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220156889A (cg-RX-API-DMAC10.html)
CN (2) CN115551845B (cg-RX-API-DMAC10.html)
AR (1) AR121618A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021239378A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018877A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176140A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014490A2 (cg-RX-API-DMAC10.html)
IL (1) IL296631A (cg-RX-API-DMAC10.html)
MX (1) MX2022011123A (cg-RX-API-DMAC10.html)
WO (1) WO2021188936A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors

Also Published As

Publication number Publication date
CN115551845B (zh) 2025-02-28
CA3176140A1 (en) 2021-09-23
CN115551845A (zh) 2022-12-30
MX2022011123A (es) 2023-01-04
AR121618A1 (es) 2022-06-22
EP4121425A1 (en) 2023-01-25
KR20220156889A (ko) 2022-11-28
JP2026021443A (ja) 2026-02-10
JP7768890B2 (ja) 2025-11-12
US20230227426A1 (en) 2023-07-20
JP2023518953A (ja) 2023-05-09
WO2021188936A1 (en) 2021-09-23
CN119823097A (zh) 2025-04-15
BR112022018877A2 (pt) 2022-11-29
AU2021239378A1 (en) 2022-11-17
IL296631A (en) 2022-11-01
TW202140443A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
CO2022014587A2 (es) Compuestos inhibidores de phd, composiciones y uso
MX2022011123A (es) Compuestos inhibidores de phd, composiciones, y uso.
AR121626A1 (es) Compuestos inhibidores de phd, composiciones y métodos de uso
AR130425A1 (es) Inhibidores de kras(g12d)
CY1122860T1 (el) 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ(2,3,4,5,6-πενταϋδροξυεξυλ)αμινο)αιθοξυ)φαινυλ)βουτυλ)καρβαμιμιδοϋλ)πυραζινο-2-καρβοξαμιδιο
CU23967B1 (es) Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial
PE20210046A1 (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido
AR111178A1 (es) Inhibidor de la quinasa reguladora de la señal de apoptosis
AR134363A1 (es) Derivado de ácido 2-(pirrolidina-3-il)acético sustituido, método de preparación y uso de este
CL2024001620A1 (es) Inhibidores del sarcómero cardíaco
DOP2022000054A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2024011179A (es) Compuestos multiciclicos
CO2025005721A2 (es) Derivados de benzimidazol cíclico como inhibidores de cgas
CL2025001166A1 (es) Derivados de piridina cíclico como inhibidores de cgas
AR123243A1 (es) Compuestos inhibidores del phd, composiciones y métodos de uso
CO2022015205A2 (es) Procesos para la preparación de un inhibidor de cinasa
JP2021512898A5 (cg-RX-API-DMAC10.html)
BR112023000344A2 (pt) Agonistas de receptor de peptídeo de formila de pirazolona 2
AR132818A1 (es) Compuestos para la degradación de la cinasa egfr
MX2024009270A (es) Compuestos bloqueadores de canales de sodio epiteliales sustituidos con bifenilo
AR128868A1 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
AR127559A1 (es) Compuestos, composiciones y métodos
NO20081736L (no) Antitumormidler
JP2023522628A5 (cg-RX-API-DMAC10.html)
CN115066417A (zh) 凝血因子XIa抑制剂